Haleon (LON:HLN) Receives “Buy” Rating from Jefferies Financial Group

Haleon (LON:HLN)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Financial Group in a report released on Friday,Digital Look reports. They presently have a GBX 400 target price on the stock. Jefferies Financial Group’s price objective would suggest a potential upside of 8.84% from the company’s current price.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. lowered their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a report on Thursday, June 25th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Berenberg Bank restated a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research report on Thursday, April 30th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a GBX 325 price objective on shares of Haleon in a research note on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Haleon presently has a consensus rating of “Hold” and an average price target of GBX 395.33.

Haleon Stock Down 0.3%

Shares of HLN stock opened at GBX 367.50 on Friday. Haleon has a 1 year low of GBX 317.80 and a 1 year high of GBX 416.10. The stock has a market cap of £32.37 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The business’s fifty day moving average is GBX 349.45 and its 200-day moving average is GBX 363.11. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92.

Haleon (LON:HLN) last posted its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. Equities analysts expect that Haleon will post 19.5033282 earnings per share for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.